EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources

Gabriella Gálffy, Géza Tamás Szabó, Lilla Tamási, Veronika Müller, Judit Moldvay, Veronika Sárosi, Anna Kerpel-Fronius, Tamás Kardos, Edit Csada, Zsolt Pápai-Székely, Zoltán Szász, Zsolt Király und 11 weitere

Pathology and Oncology Research · 2024

DOI: 10.3389/pore.2024.1611754 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology and Oncology Research, 2024. Verfasst von Gabriella Gálffy und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, Pulmonology Center of the Reformed Church in Hungary, Törökbálint, Hungary. Hauptthemen laut MEDLINE: Lung Neoplasms, COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MSD Sharp and Dohme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Hungary has repeatedly been shown to have the highest cancer-related mortality and incidence in Europe. Despite lung cancer being the most abundant malignant diagnosis in Hungary, numerous concerns have been raised recently regarding the bias inherent to reported incidence estimates. Re-analysis of reimbursement claims has been suggested previously by our group as an alternative approach, offering revised figures of lung cancer incidence between 2011 and 2016. Leveraging on this methodology, we aimed at updating Hungarian lung cancer incidence estimates with an additional 5 years (2017–2021), including years affected by the COVID-19 pandemic. Additionally, we also attempted to improve the robustness of estimates by taking additional characteristics of the patient pathway into account.

Methods

Lung cancer patients between 2011 and 2021 were identified based on reimbursement-associated ICD-10 codes, histology codes and time patterns. Multiple query architectures were tested for sensitivity and compared to official estimates of the Hungarian National Cancer Registry (HNCR). Epidemiological trends were estimated by Poisson-regression, corrected for age and sex.

Results

A total of 89,948 lung cancer patients diagnosed in Hungary between 2011 and 2021 have been identified by our study. In 2019 alone, 7,887 patients were diagnosed according to our optimized query. ESP2013 standardized rate was estimated between 92.5/100,000 (2011) and 78.4/100,000 (2019). In 2019, standardized incidence was 106.8/100,000 for men and 59.7/100,000 for women. Up until the COVID-19 pandemic, lung cancer incidence was decreasing by 3.18% (2.1%–4.3%) yearly in men, while there was no significant decrease in women. Young age groups (40–49 and 50–59) featured the largest improvement, but women aged 60–79 are at an increasing risk for developing lung cancer. The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).

Conclusion

Our results show that using an optimized approach, re-analysis of reimbursement claims yields robust estimates of lung cancer incidence. According to this approach, the incidence rate of male lung cancer is declining in Hungary, in concordance with the trend observed for lung cancer mortality. Among women aged 60–79, the incidence of lung cancer has risen, requiring more attention in the near future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCOVID-19HumansHungaryIncidenceMaleFemaleAgedMiddle AgedAdultSARS-CoV-2Aged, 80 and overRegistriesPandemicsYoung AdultInformation Sources

Stichwörter der Autor:innen

COVID-19Hungaryincidencelung cancermortality

Autor:innen und Institutionen

  • Department of Pulmonology, Pulmonology Center of the Reformed Church in Hungary, Törökbálint, Hungary.
  • MSD Pharma Hungary Ltd., Budapest, Hungary.
  • Department of Pulmonology, Semmelweis University, Budapest, Hungary.
  • Department of Pulmonology, National Korányi Institute of Pulmonology, Budapest, Hungary.
  • Department of Pulmonology, University of Szeged Albert Szent-Györgyi Medical School, Szeged, Hungary.
  • Faculty of Medicine, University of Pécs, Pécs, Hungary.

Förderung

  • MSD Sharp and Dohme

Zitieren

APA

Gálffy, G., Szabó, G. T., Tamási, L., Müller, V., Moldvay, J., Sárosi, V., Kerpel-Fronius, A., Kardos, T., Csada, E., Pápai-Székely, Z., Szász, Z., Király, Z., Hódi, G., Kovács, Z., Balogh, É., Kovács, K. A., Darida, M., Buga, V., Rokszin, G., …, & Bogos, K. (2024). Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources. Pathology and Oncology Research. https://doi.org/10.3389/pore.2024.1611754

Vancouver

Gálffy G, Szabó GT, Tamási L, Müller V, Moldvay J, Sárosi V, et al. Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources. Pathology and Oncology Research. 2024. doi:10.3389/pore.2024.1611754

BibTeX
@article{Glffy2024,
  author = {Gálffy, Gabriella and Szabó, Géza Tamás and Tamási, Lilla and Müller, Veronika and Moldvay, Judit and Sárosi, Veronika and Kerpel-Fronius, Anna and Kardos, Tamás and Csada, Edit and Pápai-Székely, Zsolt and Szász, Zoltán and Király, Zsolt and Hódi, Gábor and Kovács, Zsuzsanna and Balogh, Éva and Kovács, Krisztina Andrea and Darida, Miklós and Buga, Viktória and Rokszin, György and Abonyi-Tóth, Zsolt and Kiss, Zoltán and Vokó, Zoltán and Bogos, Krisztina},
  title = {Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources},
  journal = {Pathology and Oncology Research},
  year = {2024},
  doi = {10.3389/pore.2024.1611754}
}
Kostenlos starten →